Extended Data Fig. 2
From: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
(a-r) Human PDAC xenograft models from Fig. 2a. (a) Waterfall plot showing tumor volume change from baseline in RMC-7977 treated tumors. Error bars indicate ±s.e.m. Table shows selected genotypes for the xenograft panel with the row above indicating the KRAS mutation and number of animals. Present co-mutations in each model shown as blue squares in the table. (b-i) Tumor growth curves for indicated xenograft models from (a), shown as percent tumor volume change from baseline over time. Vehicle and RMC-7977 groups were compared by 2-way repeated measures ANOVA on the last measurement day of the vehicle group (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). Error bars indicate ±s.e.m. (j-r) Tolerability of RMC-7977 as assessed by percent animal body weight change from baseline over time, for indicated xenograft models from (a). Error bars indicate ±s.e.m. (s,t) Kaplan-Meier survival analysis comparing RMC-7977 and Vehicle treatment arms in (s) subcutaneous and (t) orthotopic KPCY 6499c4 allograft models (***, p < 0.001; ****, p < 0.0001). (u) Quantification of phospho-ERKT202/Y204 (left) and CC3 (right) staining in tumors from orthotopic KPCY 6499c4 allograft model collected at indicated timepoints post single dose of Vehicle or RMC-7977. Analysis of IHC images based on 10 fields of view and plotted as average per tissue section. Results were compared by two-tailed Student’s unpaired t-test (**, p < 0.01; ****, p < 0.0001). Error bars indicate ±s.d.